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Abstract
To gain insight into the role of genomic alterations in breast cancer progression, we conducted a comprehensive genetic
characterization of a series of four cell lines derived from MCF10A. MCF10A is an immortalized mammary epithelial cell line
(MEC); MCF10AT is a premalignant cell line generated from MCF10A by transformation with an activated HRAS gene;
MCF10CA1h and MCF10CA1a, both derived from MCF10AT xenografts, form well-differentiated and poorly-differentiated
malignant tumors in the xenograft models, respectively. We analyzed DNA copy number variation using the Affymetrix
500 K SNP arrays with the goal of identifying gene-specific amplification and deletion events. In addition to a previously
noted deletion in the CDKN2A locus, our studies identified MYC amplification in all four cell lines. Additionally, we found
intragenic deletions in several genes, including LRP1B in MCF10CA1h and MCF10CA1a, FHIT and CDH13 in MCF10CA1h, and
RUNX1 in MCF10CA1a. We confirmed the deletion of RUNX1 in MCF10CA1a by DNA and RNA analyses, as well as the
absence of the RUNX1 protein in that cell line. Furthermore, we found that RUNX1 expression was reduced in high-grade
primary breast tumors compared to low/mid-grade tumors. Mutational analysis identified an activating PIK3CA mutation,
H1047R, in MCF10CA1h and MCF10CA1a, which correlates with an increase of AKT1 phosphorylation at Ser473 and Thr308.
Furthermore, we showed increased expression levels for genes located in the genomic regions with copy number gain.
Thus, our genetic analyses have uncovered sequential molecular events that delineate breast tumor progression. These
events include CDKN2A deletion and MYC amplification in immortalization, HRAS activation in transformation, PIK3CA
activation in the formation of malignant tumors, and RUNX1 deletion associated with poorly-differentiated malignant
tumors.
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Introduction
Human breast cancer is thought to evolve via sequential genetic
alterations from benign hyperplasia of mammary duct epithelial
cells, through atypical ductal hyperplasia, to ductal carcinoma in
situ (DCIS), invasive tumor confined to the breast, lymph node
involvement, and eventually metastases to distant organs. A
powerful cell culture model system for studying breast cancer
progression is the MCF10A series of cell lines [1,2,3]. This system
consists of multiple cancer cell lines derived from an immortalized
mammary epithelial cell (MEC) line; these isogenic cell lines
represent progression through stages of breast tumorigenesis in
much the same manner as the in vivo human breast lesions reflect
such a carcinogenic process. MCF10A is an immortalized
mammary epithelial cell line; the premalignant cell line
MCF10AT was generated by HRAS transformation of MCF10A;
MCF10CA1h and MCF10CA1a, both derived from MCF10AT
xenografts, form well-differentiated and poorly-differentiated
malignant tumors in their respective xenograft models.
The MCF10A series of cell lines has frequently been used to
study transformation activities of oncogenes and tumor suppressor
genes. Recent studies include the investigation of the effects of
ERBB2 overexpression on cell invasion [4], deletion of RB on the
epithelial-to-mesenchymal transition (EMT) [5], and PCDH8
mutations on cell transformation [6]. In addition to studies of
individual genes, several investigations have used array CGH to
analyze DNA copy number variation of MCF10A [7,8]. One such
study found a deletion of the CDKN2A locus [8], which had also
been noted in a previous cytogenetic analysis [9]. Another study
using the multiplex ligation-dependent probe amplification assay
containing 122 probe sequences uncovered gain in the MYC
region in MCF10A [10]. A recent study reported a combined
analysis of array CGH and cDNA microarray approaches for the
MCF10A series cell lines [11]. Despite the progress made using the
MCF10A model system, we still lack comprehensive knowledge of
key genetic events that drive the progression of the MCF10A series
of cell lines through the steps of immortalization, transformation,
malignant tumor formation, and tumor metastasis. Using a
combination of high density SNP arrays and mutation analysis
by sequencing, we have identified sequential genetic alterations,
both known and novel. These genetic changes include CDKN2A
deletion and MYC amplification in immortalization, HRAS
PLoS ONE | www.plosone.org 1 February 2010 | Volume 5 | Issue 2 | e9201activation in transformation, PIK3CA activation in the formation
of malignant tumors, and RUNX1 deletion associated with poorly-
differentiated malignant tumors.
Results and Discussion
Large-Scale Genomic Alterations in the MCF10A Series of
Cell Lines
To better understand the role of genetic alterations in breast
cancer progression, we performed DNA copy number analysis
using the Affymetrix 250 K Nsp and Sty SNP arrays. Genomic
changes affecting chromosomes or sub-chromosomal regions are
shown in Figure 1 for chromosomes 5, 8, 9, 10, and 19 (Plots for
other chromosomes are available in Supplementary Figure S1, and
the data are also summarized in Supplementary Figure S2A and
Supplementary Table S1). Some of the observed alterations were
present in most or all cell lines. For example, we detected copy
number gain on the long arm of chromosome 5, spanning 5q23-
qter region, in all 4 cell lines (Figure 1). This finding is in
agreement with a duplication at the tip of 5q noted in a previous
cytogenetic study [1]. Copy number gain was observed in the
19q13-qter region in MCF10A, MCF10AT, and MCF10CA1h
(Figure 1). Other genomic alterations were restricted to subsets of
the MCF10A cell line series. Among these were chromosome 20
trisomy (gain of whole chromosome) observed in the MCF10A cell
line and the loss of the 13q21 region seen in the MCF10AT cell
line (Supplementary Figures S1 and S2A).
From this analysis we found the global genomic structure of
MCF10AT to be similar to that of MCF10A except for alterations in
thefollowingthreeregions:chromosome9,13q21,andchromosome
20 (Figure 1 and Supplementary Figures S1 and S2A and Table S1).
These changes are relatively infrequent compared to the changes
foundonlyinMCF10CA1h.Thisobservationsuggeststhatrelatively
few additional genetic events were required beyond activation of the
HRAS gene in order to achieve progression from immortal but
otherwise normal MCF10A to pre-malignant MCF10AT. In
contrast to the minimal number of genomic changes in the transition
from the immortalized cell line MCF10A to the transformed cell line
MCF10AT, MCF10CA1h, the malignant cancer cell line, acquired
numerous genetic alterations relative to its MCF10AT precursor cell
line, including both copy number gain and loss (Supplementary
Figures S1 and S2A and Table S1). In contrast, at this chromosomal
level the MCF10CA1a metastatic cells appear to recapitulate the
gains and losses observed in the less aggressive cell lines. We found
copy number gain in the 3p14-qter region in the two malignant cell
lines (Supplementary Figures S1 and S2A and Table S1) and
chromosome 9 trisomy in MCF10AT, MCF10CA1h, and
MCF10CA1a cells (Figure 1). The copy number gains on
chromosomes 3 and 9 have previously been observed in a
cytogenetic study which described them as der(3)t(3;17)(p13;p12)
and +9 trisomy [3]. There were numerous unique changes in the
MCF10CA1h cell line, including the copy number gains on 1q, 2p,
14q12-q24, 15q11-q25, and 17q21-qter (Supplementary Figures S1
and S2A and Table S1), suggesting that a critical mutation which
was acquired in the MCF10CA1h lineage may be associated with
the observed genomic instability. One unique feature of the SNP
chip is its capacity for detecting loss of heterozygosity (LOH). We
identified numerous LOH regions (Supplementary Table S2). For
example, MCF10CA1a cells showed complete loss of one allele for
all SNPs on chromosomes 2 and 6 due to mitotic recombination or
chromosomal non-disjunction (Supplementary Table S2 and
Supplementary Figure S2B).
Next, we examined copy number changes affecting moderately
sized genomic regions such as those involving a single cytogenetic
band. We found copy number gain in 10q22.1 in all 4 cell lines
(Figure 1). Interestingly, although duplication in the same region,
noted as dup(10)(q22.1–22.2), was previously observed in this
series of cell lines, these earlier observations reported this
duplication to be restricted to MCF10CA1h and MCF10CA1a
[3]. A possible explanation for this discrepancy is that dup(10q22)
was present in a small fraction of the cells in MCF10A and
MCF10AT, and these dup(10q22)-positive cells were expanded to
constitute a major fraction in the MCF10A and MCF10AT cell
populations used in the current study. If this interpretation is
correct, the 19 genes located within the dup(10q22) region
(Supplementary Table S3) may have provided a selective growth
advantage. Another region with copy number gain in all 4 cell
lines was found in 17p11 (Supplementary Figures S1 and S2A and
Table S1). Additional copy number changes involving gain in
13q32 and loss in 21q11 were observed in all 4 cell lines
(Supplementary Figures S1 and S2A).
Focal Amplification and Deletion in the MCF10A Series of
Cell Lines
Many of the large-scale genomic changes observed in our
studies were also noted in previous cytogenetic studies. Our
specific interest in this project, however, was to identify small
genomic changes that affect regions a few hundred kilobases (kb) in
size, with the goal of discovering novel oncogenes and tumor
suppressor genes. To this end, we took advantage of the high
marker density of the Affymetrix 500 K microarray to identify
focal amplifications and deletions. We found MYC amplification at
chromosome 8q24 (Figure 1, Table 1) in all 4 cell lines. The MYC
amplification in MCF10A cells was only recently reported [10].
The method used by that study, however, did not define the
boundaries of the amplified region at high resolution. Our analysis
refined the region of amplification to a 2 Mb segment containing
only four genes, MYC, PVT1, FAM84B, and TMEM75.
We observed a number of focal deletion events in the MCF10A
series of cell lines. A deletion in 3p26.3, affecting the CHL1 and
CNTN6 genes, was found in all 4 cell lines (Table 1). Our analysis
also revealed homozygous deletion at the loci of CDKN2A and
CDKN2B at chromosome 9p21.3 (Figure 1, Table 1). The
homozygous deletion of CDKN2A/B was confirmed by PCR
analyses using primers that span each exon of the two genes. We
were able to detect PCR products on DNA templates isolated from
normal cells but not from the MCF10A series of cell lines (data not
shown). The CDKN2A locus homozygous deletion in MCF10A was
already known [9]. The homozygous deletion of the CDKN2A
locus was initially identified in a cytogenetic analysis [9] and was
also observed in another study using the multiplex ligation-
dependent probe amplification assay [10]. Our data narrowed
down the deletion region to a 400 kb interval encompassing the
MTAP, CDKN2B, and CDKN2A genes.
We also observed intragenic deletions within several genes
which potentially function as breast cancer tumor suppressor loci.
These included deletions which disrupted LRP1B in MCF10CA1h
and MCF10CA1a (Supplementary Figure S2C), FHIT and
CDH13 in MCF10CA1h (data not shown), and RUNX1 in
MCF10CA1a and to a lesser extent in MCF10CA1h (Figure 2A,
Table 1). We validated each of these intragenic deletions by qPCR
(quantitative PCR) (data not shown).
Molecular Characterization of RUNX1 in the MCF10A
Series of Cell Lines
We undertook a detailed molecular analysis of the RUNX1 gene
since it was deleted predominantly in MCF10CA1a, which forms
Alterations in Breast Cancer
PLoS ONE | www.plosone.org 2 February 2010 | Volume 5 | Issue 2 | e9201Figure 1. Figure 1 shows DNA copy number variation in chromosomes 5, 8, 9, 10, and 19. The graph was generated using the Affymetrix
Genome Browser. Genomic position is displayed on the x-axis and log2ratio (tumor hybridization intensity normalized by diploid HapMap reference
samples) is on the y-axis. DNA copy number gains at 5q23.1-qter, 8q24.21, and 10q22.1 are seen in all four cell lines. Homozygous deletion at the
CDKN2A locus in chromosome 9p21.3 occurs in all four cell lines. Note that the homozygous deletion (400 kb) is embedded within a hemizygous
deletion region (4 Mb). 19q13-qter copy number gain is observed in the MCF10A, MCF10AT, and MCF10CA1h cell lines.
doi:10.1371/journal.pone.0009201.g001
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called AML1, encodes the alpha subunit of the core binding factor
(CBF), which binds to the core element of many enhancer and
promoter DNA regions. Chromosomal translocations involving
this gene are commonly associated with several types of leukemia
(See [12,13] for recent reviews). However, to date no study of
RUNX1 in breast cancer has been reported.
Three wild type transcripts are encoded by the RUNX1 gene,
one long and two short transcripts. The long transcript differs from
the two short transcripts in terms of its transcription start, whereas
the two short transcripts differ from each other in their
termination sites (Figure 2B). To characterize any potential
structural changes in the long transcript, we carried out RT-
PCR using a pair of primers in exon1 and exon7, followed by
sequencing the RT-PCR products. Intragenic deletion in RUNX1,
observed in the genomic DNA in the MCF10CA1a cell line, is
expected to generate truncated transcripts (Figure 2B). In
agreement with the predicted transcript structure based on the
genomic DNA alterations that we observed, all RT-PCR products
showed a deletion of exons 2–5, with a subset of products
exhibiting an additional deletion extending through exon 6
(Figure 2B). Both aberrant transcripts maintain the RUNX1 open
reading frame, but result in the loss of the RUNT domain, which
is critical for DNA binding and protein dimerization. The same
deletions were also observed in a fraction of RT-PCR products
generated from MCF10CA1h cells, which is consistent with the
partial deletion in DNA copy number suggested in the analysis
shown in Figure 2A. Using a primer specific for the short
transcripts in qRT-PCR experiments, we showed that expression
of these transcripts was normal in MCF10A and MCF10AT cells
but reduced in MCF10CA1h cells and nearly absent in
MCF10CA1a cells (Supplementary Figure S3A).
We then characterized RUNX1 protein expression by Western
blot analysis. The RUNX1 protein was nearly absent in the
MCF10CA1a cell line (Figure 2C), in agreement with the absence
of the full-length transcript. The RUNX1 protein level was
reduced in the MCF10CA1h cell line when compared to the level
in the MCF10AT cell line, which was the precursor cell line to
both MCF10CA1h and MCF10CA1a. Thus, this protein
expression pattern is similar to that observed in RNA expression
experiments (Supplementary Figure S3A). Our results suggest that
loss of RUNX1 protein due to intragenic deletion may be a key
step in the development of the malignant breast cancer phenotype.
We recently reported DNA copy number analysis for 161
primary breast tumors using the Affymetrix 500 K SNP arrays
[14]. Using this dataset, we analyzed DNA copy number of
RUNX1 in the primary tumors. Our analysis found no evidence of
genomic alteration of the RUNX1 gene. However, tumor
heterogeneity poses a significant challenge to the detection of
intragenic deletions that are present in only a portion of a tumor
sample. To investigate gene expression of RUNX1, we performed
quantitative RT-PCR (qRT-PCR) analysis for 29 primary tumors
from which we were able to isolate high quality RNA. We also did
qRT-PCR for 11 RNA samples isolated from normal tissues
adjacent to the tumors. We found that RUNX1 expression was
down-regulated significantly in high-grade tumors compared to
low/mid-grade tumors (Figure 3A, p-value=0.044 by t-test).
Thus, our qRT-PCR analysis of RUNX1 expression in primary
tumors corroborated the study in the MCF10A series of cell lines
and supported the idea that RUNX1 is a potential tumor
suppressor gene involved in carcinogenic progression in this
model of breast cancer.
To extend RUNX1 expression analysis in primary tumors, we
performed data mining of Oncomine database (Compendia
Bioscience, Ann Arbor, MI). We found that RUNX1 expression
was progressively reduced from low- to mid- to high-grade tumors
in multiple datasets that include Ivshina breast dataset (n=289,
Figure 3B) and Lu breast dataset (n=129, Supplementary Figure
S3B). The reduction of RUNX1 expression in high-grade tumors
is highly significant (p-value=3610
213 for the Ivshina dataset and
p-value=2.5610
29 for the Lu dataset by linear regression model
analyses). Thus, the results provide further support that RUNX1 is
a candidate tumor suppressor gene involved in breast cancer
development.
Mutational Analysis of Known Oncogenes and Tumor
Suppressor Genes in the MCF10A Series of Cell Lines
To identify subtle changes such as point mutations, we
conducted sequence analysis of the tumor suppressor genes and
oncogenes that are most commonly mutated in cancer, including
TP53, PIK3CA, AKT1, HRAS, and BRAF. We carried out the
mutation analysis for the following regions of these five genes:
TP53 (exons 4–9), PIK3CA (exons 10 and 21), BRAF (exons 11 and
15), AKT1 (exon 3), and HRAS (exons 1 and 2). Besides the G12V
HRAS mutation used in the transformation experiment to derive
the premalignant cell line MCF10AT from MCF10A, the only
mutation we detected was PIK3CA H1047R, which is known to be
the most common activating mutation in the PIK3CA gene in
human cancer [15,16]. We observed this PIK3CA mutation to be
present specifically in MCF10CA1h and MCF10CA1a cells
(Figure 4A, wild type A-allele changed to mutant G-allele) but to
be absent in the precursor MCF10AT cell line. Quantitative
estimation of the mutant versus wild type allele indicated a ratio of
Table 1. Focal amplification and intragenic deletion and mutation in the MCF10 series cell lines.
chr cytoband gene type of change and comments MCF10A MCF10AT MCF10CA1h MCF10CA1a
2 2q22.1 LRP1B intragenic deletion yes yes
3 3p26.3 CHL1, CNTN6 focal deletion yes yes yes yes
3 3p14.2 FHIT intragenic deletion yes
3 3q26.32 PIK3CA H1047R mutation yes yes
8 8q24.21 MYC, PVT1, FAM84B,
TMEM75
focal amplification; MYC is
the likely target gene
yes yes yes yes
9 9p21.3 MTAP, CDKN2B,
CDKN2A
focal deletion; CDKN2A and CDKN2B
are the likely target genes
yes yes yes yes
21 21q22.12 RUNX1 intragenic deletion yes, partial yes
doi:10.1371/journal.pone.0009201.t001
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chromosome that was duplicated in der(3)t(3;17). AKT1 is often
phosphorylated at Ser473 and Thr308 when PIK3CA is activated.
Therefore, we evaluated AKT1 Ser473 and Thr308 phosphory-
lation in the 4 cell lines of the MCF10A series. As expected, we
saw a high level of phosphorylation of AKT1 Ser473 in
Figure 2. Intragenic RUNX1 deletions in the MCF10A series of cell lines. Figure 2A illustrates intragenic DNA deletion and partial
deletion in MCF10CA1a and MCF10CA1h, respectively. The deletions span the promoter regions of two of the transcripts. Note that the
transcripts are oriented from right to left in this figure. Figure 2B summarizes altered transcripts detected in MCF10CA1a cells due to
indicated genomic deletions. Deletion structure is illustrated here based on the data shown in Figure 2A. Three alternative transcripts of the
RUNX1 gene are shown here. Truncated transcripts involving removal of exons 2–5 (truncated type 1) or exons 2–6 (truncated type 2). Figure 2C
shows Western blot analysis of the RUNX1 protein in the MCF10A series of cell lines. RUNX1 protein expression was analyzed by Western
blot using anti-RUNX1 antibody. The b-actin staining shows a similar level of protein loading in all lanes. Note the dramatic reduction of the RUNX1
protein in MCF10CA1a cells. MCF10CA1h cells show a reduced level of RUNX1 protein.
doi:10.1371/journal.pone.0009201.g002
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activating PIK3CA mutation. AKT1 Thr308 phosphorylation was
also elevated in the two malignant cell lines (data not shown). Our
results are consistent with the findings of two recent papers which
reported increased phosphorylation of AKT1 in these malignant
cells; one of these reports also noted the presence of the PIK3CA
H1047R mutation in the malignant cells [17,18]. Our findings,
together with those of the previous studies, suggest that this
PIK3CA activating mutation could be the critical genetic change
driving the malignant phenotype of MCF10CA1h and
MCF10CA1a cells.
The Effect of Copy Number on Global Gene Expression
To study the impact of chromosome copy number gain on
global gene expression, we performed gene expression profiling for
the 4 cell lines using the Affymetrix Human Gene Array 1.0 ST.
Figure 3. Expression of RUNX1 gene in primary breast tumors. Figure 3A shows qRT-PCR analysis of the RUNX1 mRNA expressions
in primary breast tumors and the adjacent normal samples. 25 of 29 our analyzed tumors have histological grade information. High
histological grade tumors (n=16) have significant reduction of RUNX1 expression compared to low/mid grade tumors (n=9) or to the adjacent
normal samples (n=11). Data are summarized by box plots. The box represents gene expression values between 1
st and 3
rd quartiles; the line
denotes median. Gene expression difference between high-grade (grade 3) and low/mid-grade (grade 1 plus grade 2) is significant (pvalue=0.044, by
t-test). Figure 3B shows RUNX1 mRNA expression in Ivshina breast microarray dataset. Ivshina breast dataset consists of 289 tumors (68
Grade 1, 166 Grade 2, and 55 Grade 3). Affymetrix U133A array expression data showed progressive reduction of RUNX1 gene (reporter: 210365_at)
from Grade 1 to Grade 2 to Grade 3. The progressive reduction of RUNX1 expression in higher grade tumors is highly significant (p-value=3610
213
by linear regression analysis). Oncomine
TM (Compendia Bioscience, Ann Arbor, MI) was used for this analysis.
doi:10.1371/journal.pone.0009201.g003
Figure 4. Identification of PIK3CA mutation in the MCF10CA1h and MCF10CA1a cells. Figure 4A shows a segment of the sequencing
chromatogram of PIK3CA. MCF10A and MCF10AT cells have a wild type A-allele marked by an arrow. In contrast, MCF10CA1h and MCF10CA1a
cells exhibit predominance of the mutant G-allele in addition to the wild type A-allele. The mutation results in an amino acid change from His to Arg
at 1047 (H1047R). Figure 4B shows increased phosphorylation of AKT1 Ser473 in the MCF10CA1h and MCF10CA1a cells. An antibody
targeting phosphorylated Ser473 in AKT1 recognized specifically the phosphorylated form of the protein, which was dramatically increased in cells
containing the PIK3CA activating mutation, i.e. the MCF10CA1h and MCF10CA1a cells. b-actin served as a control for protein loading.
doi:10.1371/journal.pone.0009201.g004
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number gain using the Affymetrix 500 K SNP array. For each of
the 4 cell lines, the regions that showed copy number gain on the
500 K SNP array overlapped the genes that were interrogated for
expression on the Human Gene Array to different degrees. Thus,
for the MCF10A cell line only 6% of the 19,734 genes interrogated
by the expression array fall into regions that showed copy number
gain on the 500 K SNP chip. In contrast, 8%, 23%, and 16% of
these 19,734 genes are represented in copy number gain regions in
the cell lines of MCF10A, MCF10AT, and MCF10CA1h,
respectively. Comparisons between genomic regions with copy
number gain (Figure 5, dashed lines labeled as ‘‘CN.2’’) to those
without gain (Figure 5, solid lines labeled as ‘‘CN,=2’’, which
includes copy number neutral and copy number loss, the latter
being a rare event, see Supplementary Figure S2A) showed
increased expression levels for genes located in the regions with
DNA copy number gain. The increased gene expression in the two
malignant cell lines is highly significant (p-value=2610
29 for
MCF10CA1h and p-value=2610
212 forMCF10CA1a, t-test).
Our results contrast with those of Marella et al. [11], which
showed a lack of correlation between gene expression and copy
number alterations. Their conclusion was based on the analysis of
40 genes in the MCF10CA1a cells; they found 13 up and 18 down
regulated genes in genomic gain regions whereas 3 down and 6 up
regulated genes in the genomic loss regions. The small number of
genes analyzed in that study may not reflect the global pattern that
we have detected in terms of overall gene expression up-regulation
in genomic copy number gain regions in the MCF10CA1h and
MCF10CA1a cell lines. The genes that showed at least 4-fold
difference in some of the pair-wise comparisons among the
MCF10A, MCF10AT, MCF10CA1h, and MCF10CA1a cell lines
are included in Supplementary Tables S4, S5, S6, S7.
Gene expression profiling of human breast cancers has
identified a number of distinct molecular subtypes with different
biological properties and prognoses [19]. The MCF10A parental
cell line clusters most closely with human breast cancer cell lines of
the ‘‘Basal B’’ subtype in expression profiling [7], and it lacks
functional estrogen or progesterone receptors [20]. The trans-
formed MCF10AT cells form hyperplastic ductal structures on
xenografting that have both myoepithelial and luminal compo-
nents, suggesting that the MCF10A parental line has properties of
a bipotential breast epithelial progenitor [2]. While MCF10CA1h
tumors have a mixed histology that includes well-differentiated
regions with weak expression of estrogen receptor, the more
malignant MCF10CA1a cells form poorly differentiated tumors
that lack estrogen receptor [21]. Furthermore, in our present
study, which has focused on copy number changes, we have shown
that the HER2 locus is not amplified in any of the four cell lines.
While recognizing that there are limitations inherent in any model,
by the criteria of hormone receptor negativity and lack of
amplification of the HER2 locus, as well as by clustering of the
parental MCF10A cell line with the Basal B subgroup by
Figure 5. The effect of chromosome copy number gain on gene expression in the MCF10A series of cell lines. For each cell line, genes
are grouped into those showing copy number (CN) greater than 2 (CN .2, dashed lines) and those showing copy number equal to or less than 2
(CN #2, solid lines). Expression levels of genes are indicated along the X-axis. The Y-axis represents the cumulative distribution function (cdf), which
describes cumulative probability of gene expression less than or equal to the threshold level indicated by the value on X-axis.The data depicted in
this figure indicate show largedifference between the expression levels for genes with copy number gain (CN .2) versus those with no gain (CN #2)
only in the two malignant cell lines, MCF10CA1h and MCF10CA1a.
doi:10.1371/journal.pone.0009201.g005
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most closely model the development of the poor prognosis ‘‘basal-
like’’ subgroup of human breast cancers.
In conclusion, our genome-wide analyses have uncovered
sequential mutation events, both known and novel, which
delineate breast tumor progression. These events include CDKN2A
deletion and MYC amplification in immortalization, HRAS
activation in transformation, PIK3CA activation in the formation
of malignant tumors, and RUNX1 deletion associated with poorly-
differentiated malignant tumors.
Materials and Methods
DNA, RNA Isolation, and Microarray Experiments
DNAs were isolated using Blood and Cell Culture midi Kit
(Qiagen, Inc., Valencia, CA, USA) and RNAs were isolated using
RNeasy mini kit (Qiagen). We followed the manufacturer’s
protocol to perform DNA copy number analysis using the
Affymetrix 500 K SNP arrays and gene expression profiling
experiments using Human Gene 1.0 ST arrays.
cDNA Synthesis, RT-PCR, Cloning Sequencing and
Quantitative RT-PCR
Total RNA was treated with DNase (Ambion, Austin, TX,
USA), and cDNA was synthesized using SuperScriptH III reverse
transcriptase (Invitrogen, Carlsbad, CA, USA) with random
primers following the manufacturer’s suggested protocol. PCR
was carried out using primers specific for exon 1 and exon 7 of the
RUNX1 transcript (NM_001754). PCR products were checked by
an agarose gel electrophoresis and then cloned into pCR-TOPO
TA cloning vector (Invitrogen). Plasmids were purified using the
mini prep kit (Qiagen) and were subjected to sequencing reactions
using the ABI BigDye Terminator BDT 3.1 (Applied Biosystems,
Foster City, CA, USA). The sequencing reaction was carried out
at 96uC for 10 sec, 50uC for 5 sec, 60uC for 2 min for 25 cycles,
with the M13 forward or reverse primers, and the reaction
products were analyzed using the 3730 XL DNA Analyzer
(Applied Biosystems). Quantitative RT-PCR for RUNX1 was
carried out using Taqman gene expression master mix (Applied
Biosystems) and custom-synthesized oligos of RUNX1-forward
(GATTAGCTGAAGATCTCTGAAACGCT), RUNX1-reverse
(GTACTTGTCATGTTCTCTGTTCTCTCA) and FAM-MGB
labeled Taqman probe (CAGTGCAGAAAATTC). PCR reaction
was performed at 95uC for 15 sec and 60uC for 1 min for 40
cycles. The reaction products were analyzed with ABI Prism
7900HT sequence detection system (Applied Biosystems). Taqman
gene expression analysis against PPIA gene (Applied Biosystems,
Hs99999904_m1) was used as a control for normalizing the
amount of RNA in the reaction.
Mutation Analysis
Genomic DNA spanning exon and nearby intron sequences was
amplified using the primers described in Supplementary Table S8.
PCR was carried out in a 20 ul reaction mixture containing 1X
Buffer (Applied Biosystems), 1.5 mM Mg
++, 0.2 mM dNTP,
0.5 uM primers, 5 ng genomic DNA, and 1 U Taq DNA
polymerase (Applied Biosystems). Initial denaturing was at 95uC
for 2 min; then 40 cycles of 95uC for 45 sec, 60uC for 30 sec, and
72uC for 60 sec; this was followed by extension at 72uC for
10 min. The PCR products were subjected to sequencing
reactions using the ABI BigDye Terminator BDT 3.1 (Applied
Biosystems) and the reaction products were analyzed using the
3730 XL DNA Analyzer (Applied Biosystems).
Cell Culture and Western Blot Analysis
The MCF10A series cell lines were described in a previous
paper [1,2,3,22]. The MCF10AT subline used here was
MCF10AT1k.cl2 (herein referred to as MCF10AT), which was
the specific clone that was used to derived the tumorigenic
variants, MCF10CA1h and MCF10CA1a.cl1 (referred to here as
MCF10CA1a) [3]. MCF10A and MCF10AT cells are maintained
in DMEM/F12 medium supplemented with 5% horse serum,
10 mg/ml insulin, 20 ng/ml EGF, 0.5 mg/ml hydrocortisone, and
100 ng/ml cholera toxin. Culture medium for MCF10CA1h and
MCF10CA1a cell lines are DMEM/F12 plus 5% horse serum.
Cells for microarray gene expression analysis were cultured in
DMEM/F12 supplemented with serum replacement 1 (Sigma, St.
Louis, MO, USA). For Western blot analyses, cells grown to 70–
80% confluence in regular growth medium (for RUNX1 analysis)
or in DMEM/F12 supplemented with serum replacement 1
(Sigma) (for AKT1 phosphorylation analysis) was lysed and
collected using M-PER mammalian protein extraction reagent
(Thermo Fisher Scientific, Rockford, IL, USA). 30 ug of protein
was loaded onto a tris-glycine SDS PAGE gel (Invitrogen) and
semi-dry transferred to a nitrocellulose membrane using iBlot
(Invitrogen). Dilutions for primary antibodies were 1:250 for
RUNX1 (sc-101146, Santa Cruz Biotechnology, Santa Cruz, CA,
USA) and 1:500 for AKT1 Ser473 (M3628, Dako, Carpinteria,
CA, USA) both in 5% milk/TBST. Antibody targeting at b-actin
(A5441, 1:5,000 dilution; Sigma) wasused to assess equivalence of
protein loading. Goat anti-rabbit HRP antibody or rabbit anti-
mouse HRP antibody was used at a 1:5000 dilution and the signals
were detected by ECL.
Data analysis.
Microarray data were first normalized using the gtype-probeset-
genotype package included in Affymetrix Power Tools version
1.85. Genomic DNA was characterized using the Affymetrix
250 K Nsp and Sty arrays. The Gene Expression Omnibus (GEO)
accession number for these array data is GSE19920. Microarray
data were normalized against 127 CEPH lymphoblastoid cell lines
by quantile normalization. The output of quantile normalization is
log2ratio of sample signal intensity to reference signal intensity for
each probeset. The Affymetrix CNAT4.0 software produces a CN
(copy number) estimate as log2ratio and a CN state prediction
based on a Hidden Markov Model. For global analysis of copy
number changes, we used bandwith of 100 kb, transition_decay at
1e-7, and no outlier_smoothing. For focal amplification/deletion,
we used the bandwith of 1 kb. The CNstate ranges from 0 to 4:
normal CN corresponds to CNstate 2; CNstates 0 and 1 indicate
copy number loss; CNstates 3 and 4 correspond to copy number
gain. For gene-level copy number estimation, we calculated the
average log2ratio for all the probesets mapped within a gene,
between the transcription start and termination sites of the gene.
The gene-level log2ratio was used to identify gene amplification/
deletion in each cell line. We used Affymetrix Expression Console
Software to extract expression values generated from Human
Gene 1.0 ST array experiments. All the statistical analyses were
conducted using the R package.
Supporting Information
Figure S1 DNA copy number analysis of the MCF10A series of
cell lines. DNA copy numbers for indicated chromosomes are
shown. The graph was generated using the Affymetrix Genome
Browser. Genomic position is displayed on the x-axis and log2ratio
(tumor hybridization intensity normalized by diploid HapMap
reference samples) is on the y-axis.
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Figure S2 A. DNA copy number variation is shown with a
heatmap. The tick marks on the left show boundaries between the
two adjacent chromosomes. The color scale indicated at the bottom
depicts DNA copy number from 0 to .=4.0 (blue represents the
maximum deletion; tan represents the maximum amplification). B.
Genetic alteration at chromosomes 2, 3 and 6 inMCF10CA1a cells.
The graph was generated using Partek genomic suite software.
DNA copy number (CN) is displayed as log2 ratio against the
diploid control (inred).Allelicratio (displayed inblue) represents the
ratio of A-allele CN value divided by (A-allele + B-allele) CN value.
Cytogeneticideogramsofchromosomesaredisplayedonthex-axes.
Lossofheterozygosity(LOH)duetoeithermitoticrecombinationor
chromosomal non-disjunction in chromosomes 2 and 6 are evident
from the allele specific analysis. Chromosome 3 displays chromo-
somal gain (trisomy) in MCF10CA1a cells. Note that most of the
normal p-arm on chromosome 3 has log2(CN ratio) value of 0
(diploid) with an allelic ratio of 0.5. C. Intragenic DNA deletion
within the LRP1B locus in the MCF10CA1h and MCF10CA1a cell
lines. Intragenic deletion in LRP1B is present in the MCF10CA1a
and MCF10CA1a cell lines. Note that the transcript is oriented
from right to left in this figure.
Found at: doi:10.1371/journal.pone.0009201.s002 (2.45 MB
PDF)
Figure S3 A. Quantitative RT-PCR analysis of the RUNX1
short transcripts. A primer was designed within the 5 prime end of
exon 1 in the two short transcripts (NM_001001890 and
NM_001122607) that is absent in the long transcript
(NM_001754). Quantitative qPCR was carried out using Power
SYBR Master Mix (Applied Biosystems) and RUNX1_variant2_-
forward and RUNX1_variant2_reverse primers at 95uC for 15 sec
and 60uC for 1 min for 40 cycles. The reaction products were
analyzed with ABI Prism 7900HT sequence detection system
(Applied Biosystems). Taqman gene expression analysis against
PPIA gene (Applied Biosystems, Hs99999904_m1) was used as a
control for normalizing the amount of RNA in the reaction. The
short transcripts are expressed in MCF10A, MCF10AT, and
MCF10CA1h but absent in MCF10CA1a. Data are shown as
mean +/2 standard deviation of triplicate measurments. B.
RUNX1 gene expression analysis using Oncomine database
Breast cancer dataset showed reduced RUNX1 gene expression
in high grade tumor. Lu breast dataset (n=129) on Affymetrix
U133 Plus 2.0 array also showed reduced RUNX1 (reporter:
209360_s_at) gene expression in Grade 3 tumor (n=64) compared
to lower grade tumor (n=15 for Grade 1 and n=16 for Grade 2).
Represented in the box plots are, maximum and minimum values,
whiskers at 90th and 10th percentile, boxes at 75th and 25th
percentile, and the median. Oncomine (Compendia Bioscience,
Ann Arbor, MI) was used for analysis and visualization.
Found at: doi:10.1371/journal.pone.0009201.s003 (0.80 MB
PDF)
Table S1 This table summarizes global DNA copy number
changes at chromosomal and sub-chromosomal levels for each of
the four cell lines.
Found at: doi:10.1371/journal.pone.0009201.s004 (0.03 MB
XLS)
Table S2 This table contains the genomic regions with LOH
that were detected in MCF10AT, MCF10CA1h, and
MCF10CA1a cells. LOH was computed based on the compari-
sons between each of the 3 cell lines with the MCF10A cell line.
Found at: doi:10.1371/journal.pone.0009201.s005 (0.03 MB
XLS)
Table S3 This table has the list of genes that are mapped in
10q22.1 CN gain region.
Found at: doi:10.1371/journal.pone.0009201.s006 (0.03 MB
XLS)
Table S4 Genes display 4-fold difference in expression levels
between MCF10A andMCF10AT. The values are log2(MC-
F10AT/MCF10A). The genes included here have log2ratio .2o r
log2ratio ,22.
Found at: doi:10.1371/journal.pone.0009201.s007 (0.04 MB
XLS)
Table S5 Genes display 4-fold difference in expression levels
between MCF10AT and MCF10CA1h. The values are
log2(MCF10CA1h/MCF10AT). The genes included here have
log2ratio .2 or log2ratio ,22.
Found at: doi:10.1371/journal.pone.0009201.s008 (0.05 MB
XLS)
Table S6 Genes display 4-fold difference in expression levels
between MCF10AT and MCF10CA1a. The values are
log2(MCF10CA1a/MCF10AT). The genes included here have
log2ratio .2 or log2ratio ,22.
Found at: doi:10.1371/journal.pone.0009201.s009 (0.05 MB
XLS)
Table S7 Genes display 4-fold difference in expression levels
between MCF10CA1h and MCF10CA1a. The values are
log2(MCF10CA1a/MCF10CA1h). The genes included here have
log2ratio .2 or log2ratio ,22.
Found at: doi:10.1371/journal.pone.0009201.s010 (0.05 MB
XLS)
Table S8 This table has the primer sequences used in PCR
experiments and mutation analyses for the TP53, PIK3CA,
AKT1, HRAS, and BRAF genes.
Found at: doi:10.1371/journal.pone.0009201.s011 (0.03 MB
XLS)
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